CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer.

ABSTRACT: Cancer patients have increased morbidity and mortality from Coronavirus Disease 2019 (COVID-19), but the underlying immune mechanisms are unknown. In a cohort of 100 cancer patients hospitalized for COVID-19 at the University of Pennsylvania Health System, we found that patients with hematologic cancers had a significantly higher mortality relative to patients with solid cancers after accounting for confounders including ECOG performance status and active cancer status. We performed flow cytometric and serologic analyses of 106 cancer patients and 113 non-cancer controls from two additional cohorts at Penn and Memorial Sloan Kettering Cancer Center. Patients with solid cancers exhibited an immune phenotype similar to non-cancer patients during acute COVID-19 whereas patients with hematolog

SUBMITTER: Bange EM 

PROVIDER: S-EPMC7872363 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature